MetaCap

BGM Group Ltd. Class A (BGM)

NASDAQ: BGMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

8.130.00 (0.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BGM stock chart

Technical analysis

Key statistics

All statistics
Market cap
$108.57M
EPS (TTM)
-$4.80
Ex-dividend date
Feb 27, 2023
52-week range
0.00 – 263.70
Day range
0.00 – 0.00
Volume / Avg
127 / 6.18K
Beta
—

52-week range

$0.00$263.70

BGM stock today

BGM Group (BGM) closed at $8.13 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. Trading was light, with 127 shares changing hands, about 2% of the average daily volume. At this level, BGM sits near the bottom of its 52-week range of $0.00 to $263.70: 96.9% below the high, set on Nov 24, 2025 and 0.0% above the low.

BGM is down 92.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 96.7%. BGM Group has posted a net loss over the last twelve months (EPS of -$4.80), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About BGM Group

Company profile

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Huandi Zhao
Headquarters
Chengdu
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, BGM Group generated $37.9 million in revenue, up 51.1% from fiscal 2024. BGM Group reported a net loss of $19.9 million, compared with a loss of $1.4 million a year earlier. Gross margin was 16.6% (up from 16.4%) and operating margin -33.2%.

BGM Group annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$37.92M$25.10M$46.47M$64.86M$57.10M
Growth+51.09%-45.99%-28.35%+13.58%+14.12%
Net income$-19.94M$-1.44M$-7.78M$1.08M$3.15M
EPS (diluted)$-0.18$-0.20$-1.08$0.15$0.09

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$7.50
Ex-dividend date
Feb 27, 2023

BGM Group peers

Health Care sector
BGM peer companies
CompanyPrice% ChgMarket capCompare
SPRBSpruce Biosciences Inc.38.00-6.15%$109.21Mvs BGM
AKBAAkebia Therapeutics Inc.0.3855-8.71%$107.04Mvs BGM
MENSJyong Biotech Ltd.1.45-17.14%$110.24Mvs BGM
IMUXImmunic Inc.6.99-5.41%$111.01Mvs BGM
OKUROnKure Therapeutics Inc. Class A2.70-2.17%$111.21Mvs BGM
GNLXGenelux Corporation2.17-4.82%$103.36Mvs BGM
FHTXFoghorn Therapeutics Inc.1.72-3.37%$103.14Mvs BGM
ORGOOrganogenesis Holdings Inc. Class A0.7716-2.23%$100.16Mvs BGM

Indexes, lists and sector

BGM Group stock FAQ

What is BGM Group's stock price today?

BGM last traded at $8.13 as of Nov 20, 4:00 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.

Does BGM Group pay a dividend?

Yes. BGM Group pays $0.00 per share annually. The most recent dividend of $7.50 had an ex-dividend date of Feb 27, 2023.

Who is BGM Group's CEO?

Ms. Huandi Zhao is the chief executive officer of BGM Group Ltd. Class A.

Has BGM ever split its stock?

Yes. The most recent BGM stock split was a 1-for-30 split on Oct 1, 2026, one of 2 splits on record.

What is the BGM 52-week high?

The 52-week high for BGM is $263.70 and the 52-week low is $0.00. The stock is currently 96.9% below its high.

Compare BGM